Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB/Alliance Studies 50402, 50701 and 50803
- Citation:
- Blood vol 128 (22) abstr 2953
- Meeting Instance:
- ASH 2016
- Year:
- 2016
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Meta-Analysis
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2817
- Pharmas:
- Celgene
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Frederick Lansigan Ian Barak Brandelyn Pitcher Sin-Ho Jung Bruce Cheson Myron Czuczman Barbara Grant Peter Martin Eric Hsi Heiko Schroder Nancy Bartlett John P. Leonard Kristie A. Blum
- Networks:
- CAPITAL, LAPS-MN026, LAPS-MO011, LAPS-NH012, LAPS-NY158, LAPS-OH007, NY018
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-50402, CALGB-50701, CALGB-50803
- Phases:
- 2
- Keywords: